OVERVIEW

European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Virtual Congress 2021 is organized by European Society for Medical Oncology (ESMO) and will be held from Mar 01 - 02, 2021.

ESMO Targeted Anticancer Therapies Virtual Congress 2021: the Home of Phase I in Oncology
The ESMO Targeted Anticancer Therapies Virtual Congress 2021, known as “The Home of Phase I in Oncology” will offer participants a glimpse of the future of targeted anticancer therapies.

It is the premier international meeting focusing on promising new anticancer targets and agents, with a particular focus on those in early phase clinical development. Stakeholders from academy and industry will discuss with clinicians, researchers, and regulators the global dissemination of knowledge and clinical research expertise in the field of innovative cancer therapeutics, to the benefit of cancer patients worldwide.

Learning objectives:
The development of novel anticancer agents in hypothesis-testing trials can transform our understanding of malignancies and impact clinical care. The TAT meeting is a meeting focused on early clinical trials and has been described as ‘The home of phase I in oncology’. This meeting will be entirely dedicated to improving the conduct of early anti-cancer clinical trials, with presentations, discussions and educational reviews, and workshops highlighting emerging pre-clinical and clinical data, as well as defining optimal methodologies for early clinical trials. Our vision is to facilitate and accelerate the early development of novel anticancer drugs. We believe that with many new therapies entering clinical testing, high quality, customized, well-designed phase I studies questioning key hypotheses and providing robust answers to these questions are critically important and will be the platform upon which therapeutics will succeed or fail.

The ESMO TAT 2021 Virtual Congress will bring together experts in anticancer drug discovery and clinical development, translational scientists, and regulators in a unique forum to highlight recent advances and new data, whilst promoting collaboration and knowledge-sharing in a bench-to-bedside approach. In addition, there are opportunities for new investigators and faculty to present their work and interact with experts, and mentoring opportunities through workshops.

In Keynote lectures, Educational sessions, Workshops, Scientific Sessions, and Poster exhibition based on abstracts selection, attendees will be able to update their knowledge on:
• Drug discovery and development for a broad range of targets
• Pre-clinical testing to identify effective combination strategies
• Immune-based therapies including ADCs, cytokines, multitargeted agents, and cell-based therapies
• The microbiome as a tool and a target
• Oncolytic viruses
• Incorporating genomics into early drug development
• Precision medicine including practical aspects of optimizing molecular tumor boards for phase I trials
• Early clinical trial methodology including design, conduct, and endpoints